Federal Project Grant Summary

Duke University received a $807,044 Project Grant award on February 6, 2026, from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, which extends through January 31, 2031, supports investigator-initiated research focused on understanding natural killer (NK) cell responses to BK polyomavirus (BKPyV) and their potential therapeutic applications. The research addresses a critical gap in infectious disease management, as BKPyV reactivation in immunocompromised hosts—particularly kidney transplant recipients—currently lacks effective treatment options and represents a leading cause of graft loss.

The project will advance scientific knowledge of NK cell-mediated antiviral immunity through research examining specific NK cell subsets that demonstrate potent cytotoxic responses against BKPyV. Key deliverables include characterization of NK cell phenotypic profiles associated with successful viral control, investigation of checkpoint receptors regulating NK cell responses, and identification of clonal NK cell populations suitable for immunotherapy development. The research will generate foundational data to support the development of NK cell-based immunotherapies as an alternative or complementary approach to existing immune-based treatments for BKPyV-associated diseases in immunosuppressed populations, addressing urgent therapeutic needs in transplant medicine.